COMMUNIQUÉS West-GlobeNewswire
-
SK pharmteco lance SKyvec™, une plateforme unifiée de vecteurs viraux à haut rendement destinée à accélérer le développement des thérapies géniques, de la fabrication au patient
23/06/2026 -
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06/2026 -
Applied Biologics Announces Submission of Abstract of Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of The Campx Trial to SAWC Fall 2026
23/06/2026 -
Clariane announces the success of its offering of €333 million of hybrid notes
23/06/2026 -
RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
23/06/2026 -
RoenRx Releases 2026 Weight-Loss Program Pricing and Treatment Cost Overview
23/06/2026 -
Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 ($55,000 CAD based on current exchange rate) research grant to advance microbiota research in human health & disease
23/06/2026 -
TogetherTuesday: Arizona Nonprofit Surpasses $6 Million for Childhood Blindness Research
23/06/2026 -
Lungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs
23/06/2026 -
GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités
23/06/2026 -
Zealthy Launches Enhanced Weight-Loss Care Platform With Integrated Zepbound Access and Insurance Support
23/06/2026 -
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026 -
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026 -
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
23/06/2026 -
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026 -
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
23/06/2026 -
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026 -
Integra LifeSciences Announces Key Executive Appointments
23/06/2026 -
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
23/06/2026
Pages